Single-agent immunotherapy clinical trials in human PDA have particularly been ineffective, thought in part to be due to decreased PD-1/PD-L1 expression compared to other tumors, but many ongoing studies are examining combinations, including with cytotoxic chemotherapy and radiation [75, 201]. This evidence concerns the gene CD274 and Patent ductus arteriosus.